MEIRAGTX HOLDINGS PLC (MGTX)
KYG596651029 - Common Stock
We assign a fundamental rating of 3 out of 10 to MGTX. MGTX was compared to 587 industry peers in the Biotechnology industry. MGTX has a bad profitability rating. Also its financial health evaluation is rather negative. MGTX has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
MGTX had negative earnings in the past year.
In the past year MGTX has reported a negative cash flow from operations.
MGTX had negative earnings in each of the past 5 years.
In the past 5 years MGTX reported 4 times negative operating cash flow.
1.2 Ratios
MGTX has a Return On Assets of -23.96%. This is in the better half of the industry: MGTX outperforms 77.61% of its industry peers.
Looking at the Return On Equity, with a value of -60.88%, MGTX is in the better half of the industry, outperforming 60.34% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.96% | ||
| ROE | -60.88% | ||
| ROIC | N/A |
ROA(3y)-30.43%
ROA(5y)-24.83%
ROE(3y)-71.28%
ROE(5y)-53.37%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MGTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MGTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
MGTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MGTX has more shares outstanding
MGTX has a better debt/assets ratio than last year.
2.2 Solvency
MGTX has an Altman-Z score of -2.62. This is a bad value and indicates that MGTX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.62, MGTX is in line with its industry, outperforming 45.30% of the companies in the same industry.
MGTX has a Debt/Equity ratio of 0.59. This is a neutral value indicating MGTX is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.59, MGTX is not doing good in the industry: 73.85% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.59 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.62 |
ROIC/WACCN/A
WACC9.89%
2.3 Liquidity
A Current Ratio of 3.14 indicates that MGTX has no problem at all paying its short term obligations.
MGTX's Current ratio of 3.14 is on the low side compared to the rest of the industry. MGTX is outperformed by 65.47% of its industry peers.
A Quick Ratio of 3.14 indicates that MGTX has no problem at all paying its short term obligations.
MGTX has a worse Quick ratio (3.14) than 63.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.14 | ||
| Quick Ratio | 3.14 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 28.47% over the past year.
The Revenue for MGTX has decreased by -16.47% in the past year. This is quite bad
Measured over the past years, MGTX shows a decrease in Revenue. The Revenue has been decreasing by -3.42% on average per year.
EPS 1Y (TTM)28.47%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q48.39%
Revenue 1Y (TTM)-16.47%
Revenue growth 3Y-3.42%
Revenue growth 5YN/A
Revenue growth Q2Q-79.07%
3.2 Future
MGTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.06% yearly.
The Revenue is expected to grow by 79.67% on average over the next years. This is a very strong growth
EPS Next Y21.51%
EPS Next 2Y62.9%
EPS Next 3Y31.96%
EPS Next 5Y29.06%
Revenue Next Year38.03%
Revenue Next 2Y159.92%
Revenue Next 3Y116.33%
Revenue Next 5Y79.67%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
MGTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
MGTX is valuated cheaply with a Price/Forward Earnings ratio of 3.76.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MGTX indicates a rather cheap valuation: MGTX is cheaper than 99.49% of the companies listed in the same industry.
MGTX is valuated cheaply when we compare the Price/Forward Earnings ratio to 20.47, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 3.76 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MGTX's earnings are expected to grow with 31.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y62.9%
EPS Next 3Y31.96%
5. Dividend
5.1 Amount
No dividends for MGTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MEIRAGTX HOLDINGS PLC
NASDAQ:MGTX (5/16/2024, 7:04:06 PM)
After market: 5.68 0 (0%)5.68
+0.15 (+2.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap365.28M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 3.76 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.96% | ||
| ROE | -60.88% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.59 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.14 | ||
| Quick Ratio | 3.14 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)28.47%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y21.51%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-16.47%
Revenue growth 3Y-3.42%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y